# Inovio Pharmaceuticals (INO) — Earnings

INO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ino/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.07 |
| EPS estimate | −$0.22 |
| EPS surprise | +67.70% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 12, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1055726/000105572626000023/ino-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/079dcf8b-14ec-f159-327f-fa4529219aa8.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 12, 2026 | −$0.22 | −$0.07 | 67.70% | — | — |
| Q1 2026 | May 13, 2026 | −$0.35 | −$0.28 | 20.00% | $333,333.00 | — |
| Q4 2025 | Mar 12, 2026 | −$0.36 | −$0.26 | 27.37% | — | — |
| Q3 2025 | Nov 10, 2025 | −$0.42 | −$0.87 | -106.31% | — | — |
| Q2 2025 | Aug 12, 2025 | −$0.61 | −$0.61 | 0.00% | $10,000.00 | — |
| Q1 2025 | May 13, 2025 | −$0.69 | −$0.51 | 26.30% | $12,500.00 | $65,343.00 |
| Q4 2024 | Mar 18, 2025 | −$0.84 | −$0.65 | 22.33% | $40,000.00 | $117,000.00 |
| Q3 2024 | Nov 14, 2024 | −$1.15 | −$0.89 | 22.61% | $112,833.00 | — |
| Q2 2024 | Aug 8, 2024 | −$1.10 | −$1.19 | -8.01% | $134,000.00 | $100,762.00 |
| Q1 2024 | May 13, 2024 | −$1.01 | −$1.31 | -29.28% | $158,333.00 | — |
| Q4 2023 | Mar 6, 2024 | −$1.19 | −$1.10 | 7.25% | $360,000.00 | $103,000.00 |
| Q3 2023 | Nov 9, 2023 | −$1.52 | −$1.56 | -2.63% | $116,667.00 | $388,446.00 |
| Q2 2023 | Aug 9, 2023 | −$1.74 | −$1.56 | 10.34% | $275,000.00 | $225,971.00 |
| Q1 2023 | May 10, 2023 | −$1.74 | −$1.92 | -10.34% | $275,000.00 | $114,943.00 |
| Q4 2022 | Mar 1, 2023 | −$2.02 | −$2.64 | -30.95% | $339,280.00 | $125,000.00 |
| Q3 2022 | Nov 8, 2022 | −$3.50 | −$1.80 | 48.53% | $623,167.00 | $9.2M |
| Q2 2022 | Aug 9, 2022 | −$3.72 | −$5.52 | -48.39% | $529,000.00 | $784,395.00 |
| Q1 2022 | May 10, 2022 | −$4.13 | −$4.32 | -4.65% | $773,000.00 | $199,074.00 |
| Q4 2021 | Mar 1, 2022 | −$3.79 | −$6.00 | -58.45% | $2.5M | $839,000.00 |
| Q3 2021 | Nov 9, 2021 | −$3.88 | −$3.48 | 10.22% | $873,600.00 | $291,698.00 |

## Frequently Asked Questions

### When did Inovio Pharmaceuticals (INO) last report earnings?

Inovio Pharmaceuticals last reported on Aug 12, 2026, covering fiscal Q2 2026.

### Did INO beat earnings estimates?

Yes. Inovio Pharmaceuticals reported EPS of −$0.07 for Q2 2026 against a −$0.22 estimate — a 67.70% beat.

## Similar Stocks

- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).